Paid Clinical Trials and Focus Groups by Category |
|
|
|
Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer
Interventions: Other: questionnaire administration; Procedure: gastrointestinal complications management/prevention; Procedure: quality-of-life assessment
Sponsor: Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Intervention:
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified January 2010
Condition: Erectile Dysfunction
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: CNTO888
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Contrast-enhanced ultrasound guided biopsy; Procedure: ultrasound guided systematic biopsy
Sponsors: Bracco Diagnostics, Inc; Bracco Imaging SpA
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Prostate Cancer
Interventions: Drug: ridaforolimus (MK8669); Drug: Comparator: Placebo; Drug: open-label ridaforolimus (MK8669)
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: Solid Tumors; Ovarian Neoplasms; Prostate Cancer
Interventions: Drug: Comparator: MK4827 (PARP inhibitor); Drug: Comparator: MK4827 (PARP Inhibitor)
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsor: AstraZeneca
Recruiting - verified February 2010
Conditions: Colorectal Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cell Carcinoma; Neoplasms
Intervention: Drug: CP-675,206
Sponsor: Pfizer
Recruiting - verified February 2010
All Categories ... Medical Conditions » ... Benign Prostate (BPH) » ... United Kingdom 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
